Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

NCT04803318 · tracked via the Priya Life Science China tracker

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Phase

Phase 2

Started

2021-01-01

Last updated

2024-06-25

Condition(s) studied

Solid Tumor, AdultHepatocellular Carcinoma

Investigational drug(s) / intervention(s)

Combination of three inhibitors Trametinib, Everolimus and Lenvatinib

Combination of three inhibitors Trametinib, Everolimus and Lenvatinib: Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.

Study summary

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Eligibility

Sex

ALL

Min age

18 Years

Max age

85 Years

Healthy volunteers

Inclusion Criteria: * Recurrent/Refractory advanced solid tumors * Age between 18 and 85 years * Expected life expectancy is greater than three months Exclusion Criteria: * Benign tumor * Life expectancy is less than three months * Serious medical commodities * others

Primary outcome measure(s)

Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment. — up to 36 months

Trial sites (1)

Facility	City	Region	Status
The Second Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong	Recruiting

More Second Affiliated Hospital of Guangzhou Medical University trials in China

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC Recruiting

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors Recruiting

Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors Recruiting

GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression Recruiting

SIRT for Potentially Resectable HCC Recruiting

Other trials for the same condition

A Monotherapy in Subjects With Advanced Solid Tumors Active, not recruiting

The Efficacy of Sequential RT After Triple Therapy for uHCC Enrolling by invitation

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma Recruiting

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma Active, not recruiting

Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04803318 on ClinicalTrials.gov ↗ ← All trials in China